Loading...
XETR
BIO3
Market cap1.65bUSD
Jun 06, Last price  
28.40EUR
Name

Biotest AG

Chart & Performance

D1W1MN
XETR:BIO3 chart
P/E
53.78
P/S
1.96
EPS
0.53
Div Yield, %
0.14%
Shrs. gr., 5y
—
Rev. gr., 5y
11.62%
Revenues
726m
+6.08%
000422,956,000440,191,000412,482,000422,027,000439,967,000500,800,000582,000,000589,600,000553,100,000378,100,000400,300,000419,100,000484,200,000515,600,000516,100,000684,600,000726,200,000
Net income
26m
-79.21%
00028,119,00028,020,00039,485,00048,149,00033,408,00032,000,00019,200,000-82,500,000-45,800,000-3,500,000181,700,000-4,700,000-31,400,000-63,300,000-31,600,000127,000,00026,400,000
CFO
61m
P
28,317,00026,307,00032,509,00034,489,00031,682,00077,828,00072,278,00034,726,000-7,200,000-11,400,00038,100,00065,900,00034,300,000-50,000,000-33,600,000-16,700,00033,900,000-40,500,000-2,700,00060,900,000
Dividend
May 08, 20240.04 EUR/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Biotest Aktiengesellschaft develops, manufactures, and sells biological medicines in Germany and internationally. It operates through Therapy, Plasma & Services, and Other segments. The company offers its products in hematology, clinical immunology, and intensive care medicine areas. Its products include Haemoctin and Vihuma for the treatment of haemophilia A acute therapy and prophylaxis; and Haemonine for haemophilia B acute therapy and prophylaxis. The company's products also comprise Cytotect CP biotest for cytomegalovirus infections; Fovepta for hepatitis B prophylaxis in neonates; Hepatect for prophylaxis of hepatitis B reinfection; Intratect and IgG Next Genration for primary immune and secondary antibody deficiency syndromes and autoimmune diseases, as well as neurological indications; Varitect for the treatment of varicella zoster virus infections; and Zutectra for hepatitis B re-infection prophylaxis after liver transplantation. In addition, it provides Albiomin and Biseko to restore and maintain circulating blood volume; Cofact for the treatment of clotting factors deficiency; Fibrinogen to treat congenital fibrinogen deficiency; Trimodulin for the community-acquired pneumonia and COVID-19; and Pentaglobin to treat bacterial infections. The company was formerly known as Biotest Serum-Institut GmbH and changed its name to Biotest Aktiengesellschaft in 1986. The company was founded in 1946 and is headquartered in Dreieich, Germany. As of January 21, 2022, Biotest Aktiengesellschaft operates as a subsidiary of Grifols, S.A.
URL
https://www.biotest.com/
IPO date
Oct 14, 1987
Employees
2,307
Domiciled in
DE
Incorporated in
DE

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT